US20050013863A1 - Dual drug dosage forms with improved separation of drugs - Google Patents

Dual drug dosage forms with improved separation of drugs Download PDF

Info

Publication number
US20050013863A1
US20050013863A1 US10/623,481 US62348103A US2005013863A1 US 20050013863 A1 US20050013863 A1 US 20050013863A1 US 62348103 A US62348103 A US 62348103A US 2005013863 A1 US2005013863 A1 US 2005013863A1
Authority
US
United States
Prior art keywords
drug
dosage form
release
polymeric film
prolonged
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/623,481
Inventor
Jong Lim
John Shell
Jenny Louie-Helm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assertio Therapeutics Inc
Original Assignee
Depomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/623,481 priority Critical patent/US20050013863A1/en
Application filed by Depomed Inc filed Critical Depomed Inc
Assigned to DEPOMED, INC. reassignment DEPOMED, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIM, JONG, LOUIE-HELM, JENNY, SHELL, JOHN N.
Priority to EP04778191A priority patent/EP1646368A4/en
Priority to NZ544615A priority patent/NZ544615A/en
Priority to KR1020067001176A priority patent/KR20060064048A/en
Priority to AU2004258903A priority patent/AU2004258903A1/en
Priority to MXPA06000526A priority patent/MXPA06000526A/en
Priority to CA2531721A priority patent/CA2531721C/en
Priority to PCT/US2004/022554 priority patent/WO2005009413A1/en
Priority to JP2006520295A priority patent/JP2007524644A/en
Priority to TW093121200A priority patent/TW200510001A/en
Publication of US20050013863A1 publication Critical patent/US20050013863A1/en
Priority to US13/530,631 priority patent/US8685450B2/en
Priority to US14/199,972 priority patent/US8999388B2/en
Priority to US14/642,013 priority patent/US9572780B2/en
Assigned to DEERFIELD PRIVATE DESIGN FUND III, L.P. reassignment DEERFIELD PRIVATE DESIGN FUND III, L.P. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DEPOMED, INC.
Priority to US15/422,275 priority patent/US20170202817A1/en
Assigned to ASSERTIO THERAPEUTICS, INC. reassignment ASSERTIO THERAPEUTICS, INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: DEPOMED, INC.
Assigned to ASSERTIO THERAPEUTICS, INC. reassignment ASSERTIO THERAPEUTICS, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBERS 09402976, 10196590, 11562002,11562173,12047388,13078575,13541314,13541325, 14747289 PREVIOUSLY RECORDED ON REEL 047322 FRAME 0843. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Assignors: DEPOMED, INC.
Assigned to ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.) reassignment ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.) RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: DEERFIELD PRIVATE DESIGN FUND III, L.P., AS COLLATERAL AGENT
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • This invention is in the field of pharmacology, and relates to drug dosage forms that are designed to deliver drugs concurrently in both immediate-release and prolonged-release delivery profiles.
  • Certain pharmacological therapies either require or benefit from the sequential administration of two or more drugs. While this can be accomplished if the administration is done according to a strict time schedule, many patients have difficulty complying with such a schedule without the assistance of a medical professional. Some therapies involve only an immediate but rapidly declining high-level dosage and a prolonged dosage at a low or moderate level, the two dosages being either of the same drug or of a different drug. Even two-dosage therapies such as these however can be troublesome to maintain if a separate administration is needed for each dosage. Certain pharmaceutical formulations have therefore been developed that combine both functions into a single dosage form. This simplifies the therapy and reduces or eliminates the chances of improper administration.
  • the prolonged-release matrix As the prolonged-release matrix swells, some of the drug intended for immediate release enters the prolonged-release matrix.
  • the immediate-release drug When the immediate-release drug is applied as a suspension of particles, the particles tend to become trapped in the prolonged-release matrix. High-potency drugs that are intended for immediate release are therefore retained rather than released.
  • the problem can be particularly acute when the drug is insoluble or of low solubility, since unintended retention of the drug in the prolonged-release portion can significantly reduce the amount of the drug that is available for absorption into the patient's bloodstream.
  • a drug dosage form that includes a prolonged-release core and an immediate-release layer or shell can be manufactured in a manner that reduces or prevents any migration of drug from the immediate-release portion into the prolonged-release portion, by interposing a thin protective layer of drug-free polymer between the prolonged-release and immediate-release portions.
  • the protective layer is penetrable by, or dissolved in, water or gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core.
  • the protective layer remains intact however during the application of the immediate-release layer, substantially reducing or eliminating any penetration by the immediate-release drug.
  • the protective layer thereby allows immediate release of the entire dose of drug in the outer layer.
  • the inclusion of the protective layer also serves to prevent interaction of the prolonged-release and immediate-release drugs, which is of value in cases where interaction between the two drugs may be detrimental to the activity of either or both of the drugs.
  • the immediate-release layer is applied either as a solution of the drug in an aqueous or organic solvent or as a suspension of solid particles of the drug in an aqueous or organic liquid carrier.
  • the liquid carrier also contains dissolved, dispersed or suspended polymer to assist in the formation of an immediate release coating.
  • the discovery is of particular interest as applied to immediate-release layers applied as suspensions of solid particles, but also those that are applied as solutions.
  • a disclosure of certain dosage forms in which the immediate-release layer is prepared from particulate suspensions is found in commonly owned, co-pending U.S. patent application Ser. No. 10/066,146, filed Feb. 1, 2002, entitled “Manufacture of Oral Dosage Forms Delivering Both Immediate-Release and Sustained-Release Drugs,” Lim et al., inventors, the contents of which are incorporated herein by reference.
  • the dosage forms of this invention are designed for oral ingestion, and the prolonged-release portion of the dosage form is one that delivers its drug to the digestive system continuously over a period of time of at least an hour and preferably several hours.
  • the drug is retained in a matrix or supporting body of pharmaceutically inert solid, and the prolonged delivery rate can be achieved by using a matrix that allows the gastrointestinal fluid to permeate the matrix and leach out the drug (i.e., allow the drug to diffuse out from the matrix as the drug slowly dissolves in the permeating fluid), or a matrix that slowly dissolves or erodes to expose the drug to the gastrointestinal fluid, or one that dissolves or erodes while allowing the gastrointestinal fluid to permeate.
  • the delivery rate is preferably slow enough that at least about 40% of the drug remains unreleased one hour after ingestion, more preferably at least about 60% and most preferably at least about 80%.
  • the drug will be substantially all released within about ten hours and preferably within about eight hours, and in many cases, the matrix supporting the drug will remain substantially intact until all of the drug is released. “Substantially intact” in this sense means that the matrix retains at least most of its size and shape rather than dissolving or disintegrating into fragments.
  • the term “prolonged-release” is equivalent to the terms “controlled-release” and “sustained-release” as used in the prior art.
  • the supporting matrix in the prolonged-release portion of the tablet is a material that swells upon contact with gastrointestinal fluid to a size that is large enough to promote retention in the stomach while the subject is in the digestive state, which is also referred to as the postprandial or “fed” mode.
  • the “fed” mode is one of two modes of activity of the stomach that differ by their distinctive patterns of gastroduodenal motor activity.
  • the “fed” mode is induced by food ingestion and begins with a rapid and profound change in the motor pattern of the upper gastrointestinal (GI) tract. The change consists of a reduction in the amplitude of the contractions that the stomach undergoes and a reduction in the pyloric opening to a partially closed state.
  • the result is a sieving process that allows liquids and small particles to pass through the partially open pylorus while indigestible particles that are larger than the pylorus are retropelled and retained in the stomach.
  • This process causes the stomach to retain particles that are greater than about 1 cm in size for about 4 to 6 hours.
  • the prolonged-release matrix in these embodiments of the invention is therefore selected as one that swells to a size large enough to be retropelled and thereby retained in the stomach, causing the prolonged release of the drug to occur in the stomach rather than in the intestines.
  • gastric-retentive (swellable) matrices contain binders that are water-swellable polymers, and suitable polymers are those that are non-toxic, that swell in a dimensionally unrestricted manner upon imbibition of water, and that release the drug gradually over time.
  • suitable polymers are those that are non-toxic, that swell in a dimensionally unrestricted manner upon imbibition of water, and that release the drug gradually over time. Examples of polymers meeting this description are:
  • copolymers of the polymers listed above including block copolymers and graft polymers.
  • specific examples of copolymers are PLURONIC® and TECTONIC®, which are polyethylene oxide-polypropylene oxide block copolymers available from BASF Corporation, Chemicals Div., Wyandotte, Mich., USA.
  • Further examples are hydrolyzed starch polyacrylonitrile graft copolymers, commonly known as “Super Slurper” and available from Illinois Corn Growers Association, Bloomington, Ill., USA.
  • Particularly preferred polymers are poly(ethylene oxide), hydroxypropyl methyl cellulose, and combinations of poly(ethylene oxide) and hydroxypropyl methyl cellulose.
  • the immediate-release portion of the dosage form is either a coating applied or deposited over the entire surface of a unitary prolonged-release core, or a single layer of a tablet constructed in two or more layers, one of the other layers being the prolonged-released portion.
  • Immediate release of the drug from the immediate-release layer is achieved in any of a variety of ways.
  • One example is by placing the drug in a layer or coating that is sufficiently thin to allow fast penetration by gastrointestinal fluid which then leaches the drug at a rapid rate.
  • Another example is by incorporating the drug in a mixture that includes a supporting binder or other inert material that dissolves readily in gastrointestinal fluid, releasing the drug as the material dissolves.
  • a third is the use of a supporting binder or other inert material that rapidly disintegrates into fine particles upon contact with gastrointestinal fluid, with both the binder particles and the drug quickly dispersing into the fluid.
  • a supporting binder or other inert material that rapidly disintegrates into fine particles upon contact with gastrointestinal fluid, with both the binder particles and the drug quickly dispersing into the fluid.
  • materials that rapidly disintegrate and disperse are lactose and microcrystalline cellulose. Hydroxypropyl methyl cellulose is a component that can serve both as a suspending agent and as a binder.
  • the dosage forms of this invention include those in which the same drug is used in both the immediate-release and the prolonged-release portions as well as those in which one drug is formulated for immediate release and another drug, different from the first, is formulated for prolonged release.
  • the invention serves to assure that the full immediate-release dosage of the drug is achieved rather than loss of the immediate-release effect.
  • the invention prevents the two drugs from commingling to the detriment of one or the other and assures that the full immediate-release dosage is achieved rather than a portion being lost to the prolonged-release region of the dosage form.
  • This invention extends to both high-solubility and low-solubility drugs, as well as drugs that are combined with an additive that serves to solubilize the drug or suspend it in a liquid carrier. Any of these drugs can be used as the immediate-release drug. Immediate-release drugs that are either sparingly soluble or insoluble in water, regardless of the solubility of the prolonged-release drug, are of particular interest in certain embodiments of this invention.
  • the immediate-release drug in these dosage forms is of sufficiently low solubility that it remains a solid particle during the preparation of the dosage form.
  • the dispersing medium is water or an aqueous solution that may contain other components.
  • the term “at most sparingly soluble” as used herein denotes a drug having a solubility in water at 25° C. that is generally less than 2% by weight, preferably less than 0.5% by weight.
  • the preferred particle size is equal to or less than about 25 microns in diameter, more preferably equal to or less than about 10 microns in diameter, still more preferably within the range of from about 0.3 micron to about 10 microns in diameter, and most preferably with the range of from about 1 micron to about 5 microns in diameter, all on a weight-average basis.
  • This invention is also applicable to dosage forms in which the dispersing medium for the immediate-release drug is an organic liquid, such as for example, ethanol, hexanes, chloroform, carbon tetrachloride, or dimethyl sulfoxide.
  • an organic liquid such as for example, ethanol, hexanes, chloroform, carbon tetrachloride, or dimethyl sulfoxide.
  • the intermediate layer of drug-free polymer that serves as a barrier to migration of the immediate-release drug into the prolonged-release matrix during application of the immediate-release layer can be applied over the prolonged-release segment as a solution or a suspension of the polymer, in the same manner by which the immediate-release drug is applied over the barrier layer.
  • the polymer is one that is penetrable by gastrointestinal fluid and can be either soluble in gastrointestinal fluid or insoluble but erodible upon contact with gastrointestinal fluid, or simply insoluble.
  • the polymer can also be one that swells upon imbibition of water in the same manner as the prolonged-release matrix.
  • Polymers that are soluble or erodible in gastrointestinal fluid will be those of which a sufficient amount remains during the formation of the immediate-release layer to serve as a barrier until the immediate-release layer is fully applied and dried.
  • the ability of the polymer to do this may vary with the thickness of the layer, the molecular weight of the polymer and, for swellable polymers, the swelling characteristics of the polymer.
  • a small degree of swellability may be favorable to accommodate any swelling of the prolonged-release matrix that may occur during the application of the polymer over the matrix without creating fissures in the polymer layer.
  • the same polymers listed above for use as the matrix in the prolonged-release portion of the dosage form can be used in the barrier layer. In many cases, it will be beneficial to use the same polymer as both the prolonged-release matrix and the barrier layer, for purposes of compatibility between the core and the barrier.
  • the matrix is a mixture of polymers
  • the barrier polymer can be one or more of the polymers of the mixture.
  • a form of the polymer having a lower molecular weight is preferably used in the barrier layer since a polymer of lower molecular weight will more readily release the immediate-release drug to the gastric environment.
  • Preferred polymers for use in forming the film are poly(ethylene oxide) hydroxypropyl methyl cellulose, poly(vinyl alcohol), combinations of poly(ethylene oxide) and hydroxypropyl methyl cellulose, and combinations of poly(vinyl alcohol) and poly(ethylene oxide).
  • the amount of the polymer in the intermediate layer may affect the barrier characteristics of the layer but it may also affect the performance of the dosage form upon ingestion, i.e., the intermediate layer may further lower the rate of release of drug from the prolonged-release portion once the prolonged-release portion is exposed. In general, however, the amount can vary widely. In most cases, best results will be achieved when the weight ratio of the polymer in the intermediate layer to the prolonged-release core is from about 0.005:1 to about 0.2:1, preferably from about 0.01:1 to about 0.1:1, and most preferably from about 0.01:1 to about 0.08:1.
  • the immediate-release drug can thus be deposited as a suspension or a solution over a unitary core of the prolonged-release drug coated with the intermediate layer. Deposition can be achieved by coating techniques commonly used in the pharmaceutical formulation art, such as spraying, pan coating, and the like. Alternatively, the immediate-release drug can be combined with particles of a binding matrix and compressed over a preformed layer of the prolonged-release drug to form a layered tablet. In either case, the immediate-release coating or layer separates relatively quickly from the remainder of the tablet after ingestion, leaving the remainder intact.
  • drugs for use in either the prolonged-release or immediate-release portions of the dosage form is not critical to the invention, and many different types of drugs can be used. The selection will depend on the condition to be treated, the therapy being sought and the needs of the particular patient. Drugs of high solubility in water as well as drugs of low solubility can occupy either the prolonged-release or immediate-release portions.
  • high-solubility drugs are metformin hydrochloride, vancomycin hydrochloride, captopril, lisinopril, erythromycin lactobionate, ranitidine hydrochloride, sertraline hydrochloride, ticlopidine hydrochloride, baclofen, amoxicillin, cefuroxime axetil, cefaclor, clindamycin, levodopa, doxifluridine, tramadol, fluoxetine hydrochloride, bupropion, potassium chloride, and esters of ampicillin.
  • low solubility drugs are saguinavir, ritonavir, nelfinavir, thiamphenicol, ciprofloxacin hydrochloride, calcium carbonate, clarithromycin, azithromycin, ceftazidime, acyclovir, ganciclovir, cyclosporin, digoxin, paclitaxel, iron salts, topiramate, ketoconazole, and sulfonylureas such as glimepiride, glyburide, and glipizide.
  • Other drugs suitable for use will be apparent to those skilled in the art.
  • One of the many areas of interest for this invention are combinations of a diuretic and either an angiotensin converting enzyme inhibitor or an angiotensin II antagonist.
  • the angiotensin converting enzyme inhibitor or angiotensin II antagonist will occupy the immediate-release portion and the diuretic the prolonged-release portion, although for certain patients a more appropriate dosage form may be one in which the diuretic occupies the immediate-release portion and the angiotensin converting enzyme inhibitor or angiotensin II antagonist occupies the prolonged-release portion.
  • Lisinopril is an example of an angiotensin converting enzyme inhibitor, and examples of other similar drugs are enalapril, captopril, fosinopril, quinapril, ramipril, and benazepril.
  • Losartan is an example of an angiotensin II antagonist, and examples of other drugs of this class that might be used are valsartan, candesartan, irbesartan, telmisartan, and eprosartan.
  • Loop diuretics i.e., those acting on the sodium-potassium symporter in the ascending loop of Henle in the kidneys to decrease the rate of readsorption of water and sodium, are also of particular interest.
  • Examples are furosemide, torsemide, ethacrynic acid, and bumetanide.
  • Thiazides and thiazide-like diuretics are believed to act primarily on the sodium-potassium symporter in the distal convoluted tubule. Examples of this type of diuretic are chlorothiazide and its sodium, salt, bendoflumethazide, hydroflumethazide, trichlorthiazide, chlorthalidone, indapamide, metolazone, quinethazone and hydrochlorothiazide. Potassium-sparing diuretics act in the late distal tubule and collecting duct. Exampes are amiloride hydrochloride and triamterene.
  • Another class of combinations of particular interest is metformin hydrochloride as the prolonged-release drug, and a glitazone as the immediate-release drug.
  • glitazones are rosiglitazone (maleate), pioglitazone, and troglitazone.
  • pyridoxine hydrochloride as the immediate-release drug
  • statins are atorvastatin, simvastatin, pravastatin, lovastatin, cerivastatin, rosuvastatin, and fluvastatin. Of these, atorvastatin and simvastatin are preferred.
  • the amounts of drugs in the immediate-release and prolonged-release portions can vary widely, depending on the potencies of the drugs and the desired dosage rates. Amounts of either drug in a single dosage form can range from about 1 mg to about 1,000 mg. In most cases the appropriate amounts will range from about 5 mg to about 500 mg. This paragraph sets forth a number of examples, others of which will be readily apparent to those skilled in the formulation and prescription of these drugs.
  • a preferred dosage range of the diuretic is 10-120 mg.
  • Lisinopril when present is preferably in an amount of about 5 mg to about 40 mg.
  • Losartan when present is preferably in an amount of about 10 mg to about 100 mg.
  • Loop diuretics when present are preferably in an amount of about 5 mg to about 200 mg.
  • metformin hydrochloride is used as the prolonged-release drug with a glitazone in the immediate-release layer
  • a 500-mg metformin hydrochloride dose for example, can be accompanied by a 4-8-mg dose of a glitazone such as rosiglitazone maleate.
  • the amount of drug in the immediate-release portion will exceed the amount in the prolonged-release portion.
  • Dosage forms for example that contain pyridoxine hydrochloride as the immediate-release drug and a statin such as atorvastatin or simvastatin as the prolonged-release drug may contain 100-200 mg of pyridoxine hydrochloride and either 20-40 mg of atorvastatin or 40-80 mg of simvastatin.
  • Preferred dosage forms in accordance with this invention are tablets, and the size, shape, and dimensions of the tablets are not critical to the invention.
  • the tablet upon swelling is preferably large enough to reach the dimensions that will cause it to be retained in the stomach during the fed mode.
  • the tablet may be circular or elongated.
  • An elongated tablet may be 18 to 22 mm in length, 6.5 to 10 mm in width, and 6.2 to 7.5 mm in height.
  • a specific example is one that is 20 mm in length, 6.7 mm in width, and 6.4 mm in height. Again, these are merely examples; the shapes and sizes can be varied considerably.
  • Tablets in accordance with this invention can be prepared by conventional mixing, comminution, and tableting techniques that are well known in the pharmaceutical industry.
  • the prolonged-release portion can for example be fabricated by direct compression in punches and dies fitted to a rotary tablet press, or by ejection or compression molding, granulation followed by compression, or the formation of a paste that is then extruded into a mold or into an extrudate which is then cut into short lengths.
  • the intermediate (barrier) layer can be applied as a coating over the prolonged-release portion by spraying, dipping, or pan-coating, and the immediate-release portion can be applied as a coating over the intermediate layer by the same techniques, or as an additional layer by tableting or compression in the same manner as the prolonged-release portion.
  • This example illustrates the preparation of tablets in accordance with this invention that contain 500 mg metformin hydrochloride as the prolonged-release component and 1 mg glimepiride as the immediate-release component.
  • Pre-formed tablets containing 500 mg of metformin hydrochloride in a matrix of hydroxypropyl methyl cellulose, poly(ethylene oxide), microcrystalline cellulose, and magnesium stearate were used as a starting material.
  • a barrier layer solution was prepared by dissolving OPADRY® YS-1-19025-A Clear (“OPADRY Clear,” hydroxypropyl methyl cellulose, available from Colorcon, West Point, Pa., USA) in purified water to a concentration of 8 weight percent. This solution was sprayed onto the metformin hydrochloride tablets until the tablet weight increased by approximately 1%.
  • a suspension for applying the immediate-release layer was prepared by dissolving polyethylene sorbitan monooleate in purified water, dispersing glimepiride (micronized, 2-4 micron average particle size) in the solution, and adding OPADRY Clear.
  • the resulting suspension contained 0.24% polyethylene sorbitan monooleate, 0.20% glimepiride, 7.56% OPADRY Clear, with water as the balance.
  • the suspension was sprayed onto the barrier layer on the metformin hydrochloride tablets until the tablet weight increased by approximately 4%.
  • This example likewise illustrates the preparation of tablets in accordance with this invention that contain metformin hydrochloride as the prolonged-release component and glimepiride as the immediate-release component, but with a higher amount of glimepiride (2 mg) than Example 1.
  • Pre-formed metformin hydrochloride tablets identical to those used as a starting material in Example 1 were used. Likewise, an identical Opadry solution was used as the barrier layer solution. This solution was sprayed onto the tablets to achieve a weight increase of 1%.
  • Example 2 To prepare the immediate-release layer, a suspension similar to that of Example 1 was prepared except that it contained 0.40% glimepiride rather than 0.20%. The suspension was sprayed onto the barrier layer until the tablet weight increased by approximately 4%.
  • This example illustrates the preparation of tablets in accordance with this invention that contain 500 mg metformin hydrochloride as the prolonged-release component and 2 mg glimepiride as the immediate-release component, but using a poly(vinyl alcohol)-poly(ethylene oxide) poly(ethylene oxide) both as the barrier layer and as a component in the immediate-release layer.
  • the poly(vinyl alcohol)-poly(ethylene oxide) used in the barrier layer is KOLLICOAT® IR, a product available from BASF Corporation, Chemicals Division, Wyandotte, Mich., USA.
  • Pre-formed metformin hydrochloride tablets identical to those used as a starting material in the preceding examples are used.
  • the barrier layer solution is then prepared by dissolving the KOLLICOAT IR in purified water to a concentration of 8% by weight. This solution is then sprayed onto the pre-formed tablets to achieve a weight increase of 1%.
  • the immediate-release drug-containing coating suspension is prepared by dissolving polyethylene sorbitan monooleate in purified water, dispersing glimepiride (micronized, 2-4 micron average particle size) in the solution, adding KOLLICOAT IR, and mixing the suspension for 45-60 minutes to allow the suspension to aerate.
  • the resulting suspension contains 0.24% polyethylene sorbitan monooleate, 0.20% glimepiride, 7.56% KOLLICOAT, with water as the balance.
  • the suspension is sprayed onto the barrier layer until the tablet weight increases by approximately 6%.
  • This example illustrates the preparation of tablets in accordance with this invention that contain 20-40 mg atorvastatin as the prolonged-release component and 100-200 mg pyridoxine hydrochloride as the immediate-release component, again using KOLLICOAT IR both as the barrier layer and as a component in the immediate-release layer.
  • Pre-formed atorvastatin tablets containing 20 or 40 mg in a matrix of hydroxypropyl methyl cellulose, poly(ethylene oxide), microcrystalline cellulose, and magnesium stearate are used as a starting material.
  • the barrier layer solution is then prepared by dissolving the KOLLICOAT IR in purified water to a concentration of 8% by weight. This solution is sprayed onto the pre-formed tablets to achieve a weight increase of 0.5-2%.
  • the immediate-release drug-containing coating suspension is prepared by dissolving with mixing the required amount of pyridoxine hydrochloride in purified water, then adding KOLLICOAT with further mixing and deacration. The resulting solution is applied to the barrier layer until the tablet weight increases by approximately 6%.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Drug tablets that include a prolonged-release core and an immediate-release layer or shell are prepared with a thin barrier layer of drug-free polymer between the prolonged-release and immediate-release portions of the tablet. The barrier layer is penetrable by gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core, but remains intact during the application of the immediate-release layer, substantially reducing or eliminating any penetration of the immediate-release drug into the prolonged-release portion.

Description

    BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • This invention is in the field of pharmacology, and relates to drug dosage forms that are designed to deliver drugs concurrently in both immediate-release and prolonged-release delivery profiles.
  • 2. Description of the Prior Art
  • Certain pharmacological therapies either require or benefit from the sequential administration of two or more drugs. While this can be accomplished if the administration is done according to a strict time schedule, many patients have difficulty complying with such a schedule without the assistance of a medical professional. Some therapies involve only an immediate but rapidly declining high-level dosage and a prolonged dosage at a low or moderate level, the two dosages being either of the same drug or of a different drug. Even two-dosage therapies such as these however can be troublesome to maintain if a separate administration is needed for each dosage. Certain pharmaceutical formulations have therefore been developed that combine both functions into a single dosage form. This simplifies the therapy and reduces or eliminates the chances of improper administration.
  • Many unitary dosage forms have been proposed that combine an immediate release drug with a prolonged release drug by placing the drugs in different layers of a tablet or by placing one drug in a quickly-dissolving or quickly-dispersing shell that surrounds the slowly dissolving or swellable core that contains the other drug. The immediate-release layer or shell is typically formed by coating the pre-formed prolonged-release portion with a solution or a suspension of the immediate-release drug and a polymer and then allowing the liquid carrier in which the drug and polymer are dissolved or suspended to evaporate, leaving a solid dry outer layer. In some cases, however, the liquid carrier tends to cause swelling of the outer surface of the prolonged-release portion. As the prolonged-release matrix swells, some of the drug intended for immediate release enters the prolonged-release matrix. When the immediate-release drug is applied as a suspension of particles, the particles tend to become trapped in the prolonged-release matrix. High-potency drugs that are intended for immediate release are therefore retained rather than released. The problem can be particularly acute when the drug is insoluble or of low solubility, since unintended retention of the drug in the prolonged-release portion can significantly reduce the amount of the drug that is available for absorption into the patient's bloodstream.
    • SUMMARY OF THE INVENTION
  • It has now been discovered that a drug dosage form that includes a prolonged-release core and an immediate-release layer or shell can be manufactured in a manner that reduces or prevents any migration of drug from the immediate-release portion into the prolonged-release portion, by interposing a thin protective layer of drug-free polymer between the prolonged-release and immediate-release portions. The protective layer is penetrable by, or dissolved in, water or gastrointestinal fluid, thereby providing full access of the gastrointestinal fluid to the prolonged-release core. The protective layer remains intact however during the application of the immediate-release layer, substantially reducing or eliminating any penetration by the immediate-release drug. The protective layer thereby allows immediate release of the entire dose of drug in the outer layer. The inclusion of the protective layer also serves to prevent interaction of the prolonged-release and immediate-release drugs, which is of value in cases where interaction between the two drugs may be detrimental to the activity of either or both of the drugs.
  • This discovery extends to dosage forms in which the immediate-release layer is applied either as a solution of the drug in an aqueous or organic solvent or as a suspension of solid particles of the drug in an aqueous or organic liquid carrier. In most cases, the liquid carrier also contains dissolved, dispersed or suspended polymer to assist in the formation of an immediate release coating. The discovery is of particular interest as applied to immediate-release layers applied as suspensions of solid particles, but also those that are applied as solutions. A disclosure of certain dosage forms in which the immediate-release layer is prepared from particulate suspensions is found in commonly owned, co-pending U.S. patent application Ser. No. 10/066,146, filed Feb. 1, 2002, entitled “Manufacture of Oral Dosage Forms Delivering Both Immediate-Release and Sustained-Release Drugs,” Lim et al., inventors, the contents of which are incorporated herein by reference.
    • DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS
  • The dosage forms of this invention are designed for oral ingestion, and the prolonged-release portion of the dosage form is one that delivers its drug to the digestive system continuously over a period of time of at least an hour and preferably several hours. The drug is retained in a matrix or supporting body of pharmaceutically inert solid, and the prolonged delivery rate can be achieved by using a matrix that allows the gastrointestinal fluid to permeate the matrix and leach out the drug (i.e., allow the drug to diffuse out from the matrix as the drug slowly dissolves in the permeating fluid), or a matrix that slowly dissolves or erodes to expose the drug to the gastrointestinal fluid, or one that dissolves or erodes while allowing the gastrointestinal fluid to permeate. The delivery rate is preferably slow enough that at least about 40% of the drug remains unreleased one hour after ingestion, more preferably at least about 60% and most preferably at least about 80%. In most cases, the drug will be substantially all released within about ten hours and preferably within about eight hours, and in many cases, the matrix supporting the drug will remain substantially intact until all of the drug is released. “Substantially intact” in this sense means that the matrix retains at least most of its size and shape rather than dissolving or disintegrating into fragments. In this specification, the term “prolonged-release” is equivalent to the terms “controlled-release” and “sustained-release” as used in the prior art.
  • In certain preferred embodiments of the invention, the supporting matrix in the prolonged-release portion of the tablet is a material that swells upon contact with gastrointestinal fluid to a size that is large enough to promote retention in the stomach while the subject is in the digestive state, which is also referred to as the postprandial or “fed” mode. The “fed” mode is one of two modes of activity of the stomach that differ by their distinctive patterns of gastroduodenal motor activity. The “fed” mode is induced by food ingestion and begins with a rapid and profound change in the motor pattern of the upper gastrointestinal (GI) tract. The change consists of a reduction in the amplitude of the contractions that the stomach undergoes and a reduction in the pyloric opening to a partially closed state. The result is a sieving process that allows liquids and small particles to pass through the partially open pylorus while indigestible particles that are larger than the pylorus are retropelled and retained in the stomach. This process causes the stomach to retain particles that are greater than about 1 cm in size for about 4 to 6 hours. The prolonged-release matrix in these embodiments of the invention is therefore selected as one that swells to a size large enough to be retropelled and thereby retained in the stomach, causing the prolonged release of the drug to occur in the stomach rather than in the intestines.
  • Disclosures of oral dosage forms that swell to sizes that will prolong the residence time in the stomach are found in U.S. Pat. No. 5,007,790 (“Sustained-Release Oral Drug Dosage Form,” Shell, inventor; Apr. 16, 1991); U.S. Pat. No. 5,582,837 (“Alkyl-Substituted Cellulose-Based Sustained-Release Oral Drug Dosage Forms,” Shell, inventor; Dec. 10, 1996); U.S. Pat. No. 5,972,389 (“Gastric-Retentive Oral Drug Dosage Forms for the Controlled Release of Sparingly Soluble Drugs and Insoluble Matter,” Shell et al., inventors; Oct. 26, 1999); International (PCT) Patent Application WO 98/55107 (“Gastric-Retentive Oral Drug Dosage Forms for Controlled Release of Highly Soluble Drugs,” Shell et al., inventors; publication date Dec. 10, 1998); U.S. patent application Publication No. US 2001/0018707 A1 (“Extending the Duration of Drug Release Within the Stomach During the Fed Mode,” Shell et al., inventors, publication date Aug. 30, 2001); and International (PCT) Patent Application WO 96/26718 (“Controlled Release Tablet,” Kim, inventor: publication date Sep. 6, 1996). Each of the documents cited in this paragraph is incorporated herein in its entirety.
  • In general, gastric-retentive (swellable) matrices contain binders that are water-swellable polymers, and suitable polymers are those that are non-toxic, that swell in a dimensionally unrestricted manner upon imbibition of water, and that release the drug gradually over time. Examples of polymers meeting this description are:
      • cellulose polymers and substituted cellulose polymers, including alkyl-substituted, hydroxyalkyl-substituted, and carboxyalkyl-substituted celluloses, specific examples being, although not limited to, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, and carboxymethylcellulose, and microcrystalline cellulose
      • polysaccharides and substituted polysaccharides (with substituents such as those listed above)
      • poly(alkylene oxide)s
      • chitosan
      • poly(vinyl alcohol)
      • xanthan gum
      • maleic anhydride copolymers
      • poly(vinyl pyrrolidone)
      • starch and starch-based polymers
      • maltodextrins
      • poly (2-ethyl-2-oxazoline)
      • poly(ethyleneimine)
      • polyurethane hydrogels
      • crosslinked poly(acrylic acid)s and substituted crosslinked poly(acrylic acid)s (with substituents such as those listed above)
  • Further examples are copolymers of the polymers listed above, including block copolymers and graft polymers. Specific examples of copolymers are PLURONIC® and TECTONIC®, which are polyethylene oxide-polypropylene oxide block copolymers available from BASF Corporation, Chemicals Div., Wyandotte, Mich., USA. Further examples are hydrolyzed starch polyacrylonitrile graft copolymers, commonly known as “Super Slurper” and available from Illinois Corn Growers Association, Bloomington, Ill., USA. Particularly preferred polymers are poly(ethylene oxide), hydroxypropyl methyl cellulose, and combinations of poly(ethylene oxide) and hydroxypropyl methyl cellulose.
  • The immediate-release portion of the dosage form is either a coating applied or deposited over the entire surface of a unitary prolonged-release core, or a single layer of a tablet constructed in two or more layers, one of the other layers being the prolonged-released portion. Immediate release of the drug from the immediate-release layer is achieved in any of a variety of ways. One example is by placing the drug in a layer or coating that is sufficiently thin to allow fast penetration by gastrointestinal fluid which then leaches the drug at a rapid rate. Another example is by incorporating the drug in a mixture that includes a supporting binder or other inert material that dissolves readily in gastrointestinal fluid, releasing the drug as the material dissolves. A third is the use of a supporting binder or other inert material that rapidly disintegrates into fine particles upon contact with gastrointestinal fluid, with both the binder particles and the drug quickly dispersing into the fluid. Examples of materials that rapidly disintegrate and disperse are lactose and microcrystalline cellulose. Hydroxypropyl methyl cellulose is a component that can serve both as a suspending agent and as a binder.
  • The dosage forms of this invention include those in which the same drug is used in both the immediate-release and the prolonged-release portions as well as those in which one drug is formulated for immediate release and another drug, different from the first, is formulated for prolonged release. In cases involving the same drug, the invention serves to assure that the full immediate-release dosage of the drug is achieved rather than loss of the immediate-release effect. In cases involving one drug for immediate release and a different drug for prolonged release, the invention prevents the two drugs from commingling to the detriment of one or the other and assures that the full immediate-release dosage is achieved rather than a portion being lost to the prolonged-release region of the dosage form.
  • This invention extends to both high-solubility and low-solubility drugs, as well as drugs that are combined with an additive that serves to solubilize the drug or suspend it in a liquid carrier. Any of these drugs can be used as the immediate-release drug. Immediate-release drugs that are either sparingly soluble or insoluble in water, regardless of the solubility of the prolonged-release drug, are of particular interest in certain embodiments of this invention. The immediate-release drug in these dosage forms is of sufficiently low solubility that it remains a solid particle during the preparation of the dosage form. In certain embodiments of the invention, the dispersing medium is water or an aqueous solution that may contain other components. The term “at most sparingly soluble” as used herein denotes a drug having a solubility in water at 25° C. that is generally less than 2% by weight, preferably less than 0.5% by weight. When the drug is in particulate form, the preferred particle size is equal to or less than about 25 microns in diameter, more preferably equal to or less than about 10 microns in diameter, still more preferably within the range of from about 0.3 micron to about 10 microns in diameter, and most preferably with the range of from about 1 micron to about 5 microns in diameter, all on a weight-average basis.
  • This invention is also applicable to dosage forms in which the dispersing medium for the immediate-release drug is an organic liquid, such as for example, ethanol, hexanes, chloroform, carbon tetrachloride, or dimethyl sulfoxide. An advantage of the use of a relatively volatile organic liquid is a rapid rate of evaporation to leave a dry coating. Organic liquids are also useful for drugs that are unstable in aqueous solutions.
  • The intermediate layer of drug-free polymer that serves as a barrier to migration of the immediate-release drug into the prolonged-release matrix during application of the immediate-release layer can be applied over the prolonged-release segment as a solution or a suspension of the polymer, in the same manner by which the immediate-release drug is applied over the barrier layer. The polymer is one that is penetrable by gastrointestinal fluid and can be either soluble in gastrointestinal fluid or insoluble but erodible upon contact with gastrointestinal fluid, or simply insoluble. The polymer can also be one that swells upon imbibition of water in the same manner as the prolonged-release matrix. Polymers that are soluble or erodible in gastrointestinal fluid will be those of which a sufficient amount remains during the formation of the immediate-release layer to serve as a barrier until the immediate-release layer is fully applied and dried. The ability of the polymer to do this may vary with the thickness of the layer, the molecular weight of the polymer and, for swellable polymers, the swelling characteristics of the polymer. A small degree of swellability may be favorable to accommodate any swelling of the prolonged-release matrix that may occur during the application of the polymer over the matrix without creating fissures in the polymer layer.
  • The same polymers listed above for use as the matrix in the prolonged-release portion of the dosage form can be used in the barrier layer. In many cases, it will be beneficial to use the same polymer as both the prolonged-release matrix and the barrier layer, for purposes of compatibility between the core and the barrier. When the matrix is a mixture of polymers, the barrier polymer can be one or more of the polymers of the mixture. When the same polymer is used in both regions, a form of the polymer having a lower molecular weight is preferably used in the barrier layer since a polymer of lower molecular weight will more readily release the immediate-release drug to the gastric environment. Preferred polymers for use in forming the film are poly(ethylene oxide) hydroxypropyl methyl cellulose, poly(vinyl alcohol), combinations of poly(ethylene oxide) and hydroxypropyl methyl cellulose, and combinations of poly(vinyl alcohol) and poly(ethylene oxide).
  • As noted above, the amount of the polymer in the intermediate layer may affect the barrier characteristics of the layer but it may also affect the performance of the dosage form upon ingestion, i.e., the intermediate layer may further lower the rate of release of drug from the prolonged-release portion once the prolonged-release portion is exposed. In general, however, the amount can vary widely. In most cases, best results will be achieved when the weight ratio of the polymer in the intermediate layer to the prolonged-release core is from about 0.005:1 to about 0.2:1, preferably from about 0.01:1 to about 0.1:1, and most preferably from about 0.01:1 to about 0.08:1.
  • The immediate-release drug can thus be deposited as a suspension or a solution over a unitary core of the prolonged-release drug coated with the intermediate layer. Deposition can be achieved by coating techniques commonly used in the pharmaceutical formulation art, such as spraying, pan coating, and the like. Alternatively, the immediate-release drug can be combined with particles of a binding matrix and compressed over a preformed layer of the prolonged-release drug to form a layered tablet. In either case, the immediate-release coating or layer separates relatively quickly from the remainder of the tablet after ingestion, leaving the remainder intact.
  • The choice of drugs for use in either the prolonged-release or immediate-release portions of the dosage form is not critical to the invention, and many different types of drugs can be used. The selection will depend on the condition to be treated, the therapy being sought and the needs of the particular patient. Drugs of high solubility in water as well as drugs of low solubility can occupy either the prolonged-release or immediate-release portions. Examples of high-solubility drugs are metformin hydrochloride, vancomycin hydrochloride, captopril, lisinopril, erythromycin lactobionate, ranitidine hydrochloride, sertraline hydrochloride, ticlopidine hydrochloride, baclofen, amoxicillin, cefuroxime axetil, cefaclor, clindamycin, levodopa, doxifluridine, tramadol, fluoxetine hydrochloride, bupropion, potassium chloride, and esters of ampicillin. Examples low solubility drugs are saguinavir, ritonavir, nelfinavir, thiamphenicol, ciprofloxacin hydrochloride, calcium carbonate, clarithromycin, azithromycin, ceftazidime, acyclovir, ganciclovir, cyclosporin, digoxin, paclitaxel, iron salts, topiramate, ketoconazole, and sulfonylureas such as glimepiride, glyburide, and glipizide. Other drugs suitable for use will be apparent to those skilled in the art.
  • One of the many areas of interest for this invention are combinations of a diuretic and either an angiotensin converting enzyme inhibitor or an angiotensin II antagonist. Preferably, the angiotensin converting enzyme inhibitor or angiotensin II antagonist will occupy the immediate-release portion and the diuretic the prolonged-release portion, although for certain patients a more appropriate dosage form may be one in which the diuretic occupies the immediate-release portion and the angiotensin converting enzyme inhibitor or angiotensin II antagonist occupies the prolonged-release portion. Lisinopril is an example of an angiotensin converting enzyme inhibitor, and examples of other similar drugs are enalapril, captopril, fosinopril, quinapril, ramipril, and benazepril. Losartan is an example of an angiotensin II antagonist, and examples of other drugs of this class that might be used are valsartan, candesartan, irbesartan, telmisartan, and eprosartan. Loop diuretics, i.e., those acting on the sodium-potassium symporter in the ascending loop of Henle in the kidneys to decrease the rate of readsorption of water and sodium, are also of particular interest. Examples are furosemide, torsemide, ethacrynic acid, and bumetanide. Thiazides and thiazide-like diuretics are believed to act primarily on the sodium-potassium symporter in the distal convoluted tubule. Examples of this type of diuretic are chlorothiazide and its sodium, salt, bendoflumethazide, hydroflumethazide, trichlorthiazide, chlorthalidone, indapamide, metolazone, quinethazone and hydrochlorothiazide. Potassium-sparing diuretics act in the late distal tubule and collecting duct. Exampes are amiloride hydrochloride and triamterene.
  • Another class of combinations of particular interest is metformin hydrochloride as the prolonged-release drug, and a glitazone as the immediate-release drug. Examples of glitazones are rosiglitazone (maleate), pioglitazone, and troglitazone. Yet another class of combinations is pyridoxine hydrochloride as the immediate-release drug, and a statin as the prolonged-release drug. Examples of statins are atorvastatin, simvastatin, pravastatin, lovastatin, cerivastatin, rosuvastatin, and fluvastatin. Of these, atorvastatin and simvastatin are preferred.
  • The amounts of drugs in the immediate-release and prolonged-release portions can vary widely, depending on the potencies of the drugs and the desired dosage rates. Amounts of either drug in a single dosage form can range from about 1 mg to about 1,000 mg. In most cases the appropriate amounts will range from about 5 mg to about 500 mg. This paragraph sets forth a number of examples, others of which will be readily apparent to those skilled in the formulation and prescription of these drugs. In dosage forms that include furosemide, for example, or other drugs of similar potency as prolonged-release diuretics, a preferred dosage range of the diuretic is 10-120 mg. Lisinopril when present is preferably in an amount of about 5 mg to about 40 mg. Losartan when present is preferably in an amount of about 10 mg to about 100 mg. Loop diuretics when present are preferably in an amount of about 5 mg to about 200 mg. When metformin hydrochloride is used as the prolonged-release drug with a glitazone in the immediate-release layer, a 500-mg metformin hydrochloride dose, for example, can be accompanied by a 4-8-mg dose of a glitazone such as rosiglitazone maleate. In some cases, the amount of drug in the immediate-release portion will exceed the amount in the prolonged-release portion. Dosage forms for example that contain pyridoxine hydrochloride as the immediate-release drug and a statin such as atorvastatin or simvastatin as the prolonged-release drug may contain 100-200 mg of pyridoxine hydrochloride and either 20-40 mg of atorvastatin or 40-80 mg of simvastatin.
  • Preferred dosage forms in accordance with this invention are tablets, and the size, shape, and dimensions of the tablets are not critical to the invention. In embodiments where a swellable matrix is used, the tablet upon swelling is preferably large enough to reach the dimensions that will cause it to be retained in the stomach during the fed mode. The tablet may be circular or elongated. An elongated tablet may be 18 to 22 mm in length, 6.5 to 10 mm in width, and 6.2 to 7.5 mm in height. A specific example is one that is 20 mm in length, 6.7 mm in width, and 6.4 mm in height. Again, these are merely examples; the shapes and sizes can be varied considerably.
  • Tablets in accordance with this invention can be prepared by conventional mixing, comminution, and tableting techniques that are well known in the pharmaceutical industry. The prolonged-release portion can for example be fabricated by direct compression in punches and dies fitted to a rotary tablet press, or by ejection or compression molding, granulation followed by compression, or the formation of a paste that is then extruded into a mold or into an extrudate which is then cut into short lengths. The intermediate (barrier) layer can be applied as a coating over the prolonged-release portion by spraying, dipping, or pan-coating, and the immediate-release portion can be applied as a coating over the intermediate layer by the same techniques, or as an additional layer by tableting or compression in the same manner as the prolonged-release portion.
  • The following examples, both actual and prophetic, are offered for purposes of illustration and are not intended to limit the scope of the invention.
    • EXAMPLE 1
  • This example illustrates the preparation of tablets in accordance with this invention that contain 500 mg metformin hydrochloride as the prolonged-release component and 1 mg glimepiride as the immediate-release component.
  • Pre-formed tablets containing 500 mg of metformin hydrochloride in a matrix of hydroxypropyl methyl cellulose, poly(ethylene oxide), microcrystalline cellulose, and magnesium stearate were used as a starting material. A barrier layer solution was prepared by dissolving OPADRY® YS-1-19025-A Clear (“OPADRY Clear,” hydroxypropyl methyl cellulose, available from Colorcon, West Point, Pa., USA) in purified water to a concentration of 8 weight percent. This solution was sprayed onto the metformin hydrochloride tablets until the tablet weight increased by approximately 1%.
  • A suspension for applying the immediate-release layer was prepared by dissolving polyethylene sorbitan monooleate in purified water, dispersing glimepiride (micronized, 2-4 micron average particle size) in the solution, and adding OPADRY Clear. The resulting suspension contained 0.24% polyethylene sorbitan monooleate, 0.20% glimepiride, 7.56% OPADRY Clear, with water as the balance. The suspension was sprayed onto the barrier layer on the metformin hydrochloride tablets until the tablet weight increased by approximately 4%.
    • EXAMPLE 2
  • This example likewise illustrates the preparation of tablets in accordance with this invention that contain metformin hydrochloride as the prolonged-release component and glimepiride as the immediate-release component, but with a higher amount of glimepiride (2 mg) than Example 1.
  • Pre-formed metformin hydrochloride tablets identical to those used as a starting material in Example 1 were used. Likewise, an identical Opadry solution was used as the barrier layer solution. This solution was sprayed onto the tablets to achieve a weight increase of 1%.
  • To prepare the immediate-release layer, a suspension similar to that of Example 1 was prepared except that it contained 0.40% glimepiride rather than 0.20%. The suspension was sprayed onto the barrier layer until the tablet weight increased by approximately 4%.
    • EXAMPLE 3
  • This example illustrates the preparation of tablets in accordance with this invention that contain 500 mg metformin hydrochloride as the prolonged-release component and 2 mg glimepiride as the immediate-release component, but using a poly(vinyl alcohol)-poly(ethylene oxide) poly(ethylene oxide) both as the barrier layer and as a component in the immediate-release layer. The poly(vinyl alcohol)-poly(ethylene oxide) used in the barrier layer is KOLLICOAT® IR, a product available from BASF Corporation, Chemicals Division, Wyandotte, Mich., USA.
  • Pre-formed metformin hydrochloride tablets identical to those used as a starting material in the preceding examples are used. The barrier layer solution is then prepared by dissolving the KOLLICOAT IR in purified water to a concentration of 8% by weight. This solution is then sprayed onto the pre-formed tablets to achieve a weight increase of 1%.
  • The immediate-release drug-containing coating suspension is prepared by dissolving polyethylene sorbitan monooleate in purified water, dispersing glimepiride (micronized, 2-4 micron average particle size) in the solution, adding KOLLICOAT IR, and mixing the suspension for 45-60 minutes to allow the suspension to aerate. The resulting suspension contains 0.24% polyethylene sorbitan monooleate, 0.20% glimepiride, 7.56% KOLLICOAT, with water as the balance. The suspension is sprayed onto the barrier layer until the tablet weight increases by approximately 6%.
    • EXAMPLE 4
  • This example illustrates the preparation of tablets in accordance with this invention that contain 20-40 mg atorvastatin as the prolonged-release component and 100-200 mg pyridoxine hydrochloride as the immediate-release component, again using KOLLICOAT IR both as the barrier layer and as a component in the immediate-release layer.
  • Pre-formed atorvastatin tablets containing 20 or 40 mg in a matrix of hydroxypropyl methyl cellulose, poly(ethylene oxide), microcrystalline cellulose, and magnesium stearate are used as a starting material. The barrier layer solution is then prepared by dissolving the KOLLICOAT IR in purified water to a concentration of 8% by weight. This solution is sprayed onto the pre-formed tablets to achieve a weight increase of 0.5-2%.
  • The immediate-release drug-containing coating suspension is prepared by dissolving with mixing the required amount of pyridoxine hydrochloride in purified water, then adding KOLLICOAT with further mixing and deacration. The resulting solution is applied to the barrier layer until the tablet weight increases by approximately 6%.
  • The foregoing is offered primarily for purposes of illustration. It will be readily apparent to those skilled in the art that further drugs can be included, and that the shapes, components, additives, proportions, methods of formulation, and other parameters described herein can be modified further or substituted in various ways without departing from the spirit and scope of the invention.

Claims (46)

1. A method for the manufacture of a pharmaceutical tablet which upon oral ingestion delivers a first drug by immediate release and a second drug by prolonged release defined as a release rate into gastrointestinal fluid that is slow enough to leave at least about 40% of said second drug unreleased one hour after ingestion, said method comprising:
(a) dispersing said second drug in a solid matrix to form a unitary body which upon immersion in gastrointestinal fluid releases said second drug by prolonged release;
(b) depositing on a surface of said unitary body a polymeric film that is devoid of either said first drug or said second drug;
(c) depositing over said polymeric film a fluid medium comprising said first drug and a liquid carrier that does not remove said polymeric film upon contact therewith; and
(d) evaporating said liquid carrier from said fluid medium thus deposited to leave a solid layer containing said first drug over said unitary body.
2. The method of claim 1 in which said solid matrix is a member selected from the group consisting of celluloses, substituted celluloses, microcrystalline cellulose, polysaccharides, substituted polysaccharides, polyl(alkylene oxide)s, poly(vinyl alcohol), starch, starch-based polymers, crosslinked poly(acrylic acid)s, and substituted crosslinked poly(acrylic acid)s.
3. The method of claim 1 in which said solid matrix is a member selected from the group consisting of poly(ethylene oxide), hydroxypropyl methyl cellulose, and combinations of poly(ethylene oxide) and hydroxypropyl methyl cellulose.
4. The method of claim 1 in which said polymeric film is a member selected from the group consisting of poly(ethylene oxide), hydroxypropyl methyl cellulose, polyvinyl alcohol, combinations of poly(ethylene oxide) and hydroxypropyl methyl cellulose, and combinations of polyvinyl alcohol and poly(ethylene oxide).
5. The method of claim 1 in which said fluid medium comprises a liquid solution of said first drug in a solvent.
6. The method of claim 1 in which said fluid medium comprises a liquid solution of said first drug and a polymer in a solvent.
7. The method of claim 1 in which said fluid medium comprises a suspension of said first drug in solid particle form in a liquid suspending agent.
8. The method of claim 1 in which said fluid medium comprises a suspension of said first drug in solid particle form and a dispersing agent, also in solid particle form, in a liquid suspending agent, said dispersing agent being a substance that separates into discrete particles upon contact with gastrointestinal fluid.
9. The method of claim 1 in which said fluid medium is an aqueous suspension of said first drug, and said first drug is comprised of particles having a weight-averaged diameter equal to or less than 25 microns.
10. The method of claim 1 in which said fluid medium is an aqueous suspension of said first drug, and said first drug is comprised of particles having a weight-averaged diameter equal to or less than 10 microns.
11. The method of claim 1 in which the weight ratio of said polymeric film to said unitary body is from about 0.005:1 to about 0.2:1.
12. The method of claim 1 in which the weight ratio of said polymeric film to said unitary body is from about 0.01:1 to about 0.1:1.
13. The method of claim 1 in which the weight ratio of said polymeric film to said unitary body is from about 0.01:1 to about 0.08:1.
14. The method of claim 1 in which (b) comprises surrounding said unitary body entirely with said polymeric film, and said solid layer of (d) is a shell completely encasing said unitary body and polymeric film.
15. The method of claim 1 in which (b) and (c) comprise depositing said polymeric film and said first drug over only a portion of the entire surface of said unitary body, leaving the remainder of said unitary body exposed.
16. The method of claim 1 in which said liquid carrier of step (c) is water.
17. The method of claim 1 in which said liquid carrier of step (c) is an organic solvent.
18. The method of claim 17 in which said organic solvent is a member selected from the group consisting of ethanol, hexanes, chloroform, carbon tetrachloride, and dimethyl sulfoxide.
19. A dosage form for delivering a first drug that is immediately releasable upon ingestion and a second drug that is releasable by prolonged release defined as a release rate that is slow enough to leave at least about 40% of said second drug unreleased one hour after ingestion, said dosage form comprising:
a prolonged-release section comprising said second drug dispersed in a solid matrix that releases said second drug by prolonged release upon immersion of said dosage form in gastrointestinal fluid;
a polymeric film adhering to a surface of said prolonged-release section, said polymeric film being penetrable by gastrointestinal fluid and devoid of both said first drug and said second drug; and
an immediate-release section comprising a solid layer adhering to said polymeric film, said solid layer comprising said first drug dispersed in a matrix that promotes immediate release of said first drug upon immersion of said dosage form in gastrointestinal fluid.
20. The dosage form of claim 19 in which said solid matrix is a member selected from the group consisting of celluloses, substituted celluloses, microcrystalline cellulose, polysaccharides, substituted polysaccharides, polyl(alkylene oxide)s, poly(vinyl alcohol), starch, starch-based polymers, crosslinked poly(acrylic acid)s, and substituted crosslinked poly(acrylic acid)s.
21. The dosage form of claim 19 in which said solid matrix is a member selected from the group consisting of poly(ethylene oxide), hydroxypropyl methyl cellulose, and combinations of poly(ethylene oxide) and hydroxypropyl methyl cellulose.
22. The dosage form of claim 19 in which said polymeric film is a member selected from the group consisting of poly(ethylene oxide), hydroxypropyl methyl cellulose, polyvinyl alcohol, combinations of poly(ethylene oxide) and hydroxypropyl methyl cellulose, and combinations of polyvinyl alcohol and poly(ethylene oxide).
23. The dosage form of claim 19 in which said solid matrix of said unitary body is defined as a first solid matrix and said fluid medium comprises said first drug in particle form and a second solid matrix, also in particle form, said second solid matrix being a substance that separates into discrete particles upon immersion in gastrointestinal fluid.
24. The dosage form of claim 19 in which the weight ratio of said polymeric film to said unitary body is from about 0.005:1 to about 0.2:1.
25. The dosage form of claim 19 in which the weight ratio of said polymeric film to said unitary body is from about 0.01:1 to about 0.1:1.
26. The dosage form of claim 19 in which the weight ratio of said polymeric film to said unitary body is from about 0.01:1 to about 0.08:1.
27. The dosage form of claim 19 in which said polymeric film and said immediate-release section constitute a shell that fully encases said prolonged-release section.
28. The dosage form of claim 19 in which said polymeric film and said immediate-release section cover a portion of the surface of said prolonged-release section, leaving the remainder of said prolonged-release section exposed.
29. The dosage form of claim 19 in which one of said first and second drugs is a diuretic and the other is a member selected from the group consisting of angiotensin converting enzyme inhibitors and angiotensin II antagonists.
30. The dosage form of claim 29 in which said diuretic is a loop diuretic.
31. The dosage form of claim 30 in which said loop diuretic is a member selected from the group consisting of furosemide, torsemide, ethacrynic acid, and bumetanide.
32. The dosage form of claim 29 in which said diuretic is a thiazide diuretic.
33. The dosage form of claim 34 in which said thiazide diuretic is a member selected from the group consisting of chlorothiazide, bendoflumethazide, hydroflumethazide, trichlorthiazide, chlorthalidone, indapamide, metolazone, quinethazone and hydrochlorthiazide.
34. The dosage form of claim 29 in which said diuretic is a potassium-sparing diuretic.
35. The dosage form of claim 34 in which said potassium-sparing diuretic is a member selected from the group consisting of amiloride hydrochloride and triamterene.
36. The dosage form of claim 19 in which said first drug is a member selected from the group consisting of lisinopril and losartan, and said second drug is a diuretic.
37. The dosage form of claim 19 in which said first drug is a glitazone, and said second drug is metformin hydrochloride.
38. The dosage form of claim 19 in which said first drug is pyridoxine hydrochloride, and said second drug is a member selected from the group consisting of atorvastatin, simvastatin, pravastatin, lovastatin, cerivastatin, rosuvastatin, and fluvastatin.
39. The dosage form of claim 19 in which said first drug is pyridoxine hydrochloride, and said second drug is a member selected from the group consisting of atorvastatin and simvastatin.
40. The dosage form of claim 19 in which said second drug is a member selected from the group consisting of metformin hydrochloride, vancomycin hydrochloride, captopril, erythromycin lactobionate, ranitidine hydrochloride, sertraline hydrochloride, ticlopidine hydrochloride, amoxicillin, cefuroxime axetil, cefaclor, clindamycin, doxifluridine, tramadol, fluoxitine hydrochloride, ciprofloxacin hydrochloride, gancyclovir, bupropion, lisinopril, cefaclor, saguinavir, ritonavir, nelfinavir, clarithromycin, azithromycin, ceftazidine, cyclosporin, digoxin, paclitaxel, iron salts, topiramate, and ketoconazole.
41. The dosage form of claim 19 in which said second drug is a member selected from the group consisting of lisinopril, enalapril, captopril, fosinopril, quinapril, ramipril, and benazepril.
42. The dosage form of claim 19 in which said second drug is a member selected from the group consisting of losartan, valsartan, candesartan, irbesartan, telmisartan, and eprosartan.
43. The dosage form of claim 19 in which said first drug is a sulfonylurea selected from the group consisting of glimepiride, glyburide, and glipizide, and said second drug is metformin hydrochloride.
44. The dosage form of claim 19 in which said first drug is glimepiride and said second drug is metformin hydrochloride.
45. The dosage form of claim 19 in which said first drug is glyburide and said second drug is metformin hydrochloride.
46. The dosage form of claim 19 in which said first drug is glipizide and said second drug is metformin hydrochloride.
US10/623,481 2003-07-18 2003-07-18 Dual drug dosage forms with improved separation of drugs Abandoned US20050013863A1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US10/623,481 US20050013863A1 (en) 2003-07-18 2003-07-18 Dual drug dosage forms with improved separation of drugs
EP04778191A EP1646368A4 (en) 2003-07-18 2004-07-13 Dual drug dosage forms with improved separation of drugs
NZ544615A NZ544615A (en) 2003-07-18 2004-07-13 Dual drug dosage forms with improved separation of drugs
KR1020067001176A KR20060064048A (en) 2003-07-18 2004-07-13 Dual dosage forms with improved separation of drugs
AU2004258903A AU2004258903A1 (en) 2003-07-18 2004-07-13 Dual drug dosage forms with improved separation of drugs
MXPA06000526A MXPA06000526A (en) 2003-07-18 2004-07-13 Dual drug dosage forms with improved separation of drugs.
CA2531721A CA2531721C (en) 2003-07-18 2004-07-13 Dual drug dosage forms with improved separation of drugs
PCT/US2004/022554 WO2005009413A1 (en) 2003-07-18 2004-07-13 Dual drug dosage forms with improved separation of drugs
JP2006520295A JP2007524644A (en) 2003-07-18 2004-07-13 Dual drug dosage form with improved separation of drugs
TW093121200A TW200510001A (en) 2003-07-18 2004-07-15 Dual drug dosage forms with improved separation of drugs
US13/530,631 US8685450B2 (en) 2003-07-18 2012-06-22 Dual drug dosage forms with improved separation of drugs
US14/199,972 US8999388B2 (en) 2003-07-18 2014-03-06 Dual drug dosage forms with improved separation of drugs
US14/642,013 US9572780B2 (en) 2003-07-18 2015-03-09 Dual drug dosage forms with improved separation of drugs
US15/422,275 US20170202817A1 (en) 2003-07-18 2017-02-01 Dual drug dosage forms with improved separation of drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/623,481 US20050013863A1 (en) 2003-07-18 2003-07-18 Dual drug dosage forms with improved separation of drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/530,631 Division US8685450B2 (en) 2003-07-18 2012-06-22 Dual drug dosage forms with improved separation of drugs

Publications (1)

Publication Number Publication Date
US20050013863A1 true US20050013863A1 (en) 2005-01-20

Family

ID=34063395

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/623,481 Abandoned US20050013863A1 (en) 2003-07-18 2003-07-18 Dual drug dosage forms with improved separation of drugs
US13/530,631 Expired - Fee Related US8685450B2 (en) 2003-07-18 2012-06-22 Dual drug dosage forms with improved separation of drugs
US14/199,972 Expired - Fee Related US8999388B2 (en) 2003-07-18 2014-03-06 Dual drug dosage forms with improved separation of drugs
US14/642,013 Expired - Fee Related US9572780B2 (en) 2003-07-18 2015-03-09 Dual drug dosage forms with improved separation of drugs
US15/422,275 Abandoned US20170202817A1 (en) 2003-07-18 2017-02-01 Dual drug dosage forms with improved separation of drugs

Family Applications After (4)

Application Number Title Priority Date Filing Date
US13/530,631 Expired - Fee Related US8685450B2 (en) 2003-07-18 2012-06-22 Dual drug dosage forms with improved separation of drugs
US14/199,972 Expired - Fee Related US8999388B2 (en) 2003-07-18 2014-03-06 Dual drug dosage forms with improved separation of drugs
US14/642,013 Expired - Fee Related US9572780B2 (en) 2003-07-18 2015-03-09 Dual drug dosage forms with improved separation of drugs
US15/422,275 Abandoned US20170202817A1 (en) 2003-07-18 2017-02-01 Dual drug dosage forms with improved separation of drugs

Country Status (10)

Country Link
US (5) US20050013863A1 (en)
EP (1) EP1646368A4 (en)
JP (1) JP2007524644A (en)
KR (1) KR20060064048A (en)
AU (1) AU2004258903A1 (en)
CA (1) CA2531721C (en)
MX (1) MXPA06000526A (en)
NZ (1) NZ544615A (en)
TW (1) TW200510001A (en)
WO (1) WO2005009413A1 (en)

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058286A1 (en) * 2003-12-12 2005-06-30 Penwest Pharmaceuticals Co. Sustained release torsemide dosage forms
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
WO2007042160A1 (en) * 2005-10-08 2007-04-19 Sanofi-Aventis Deutschland Gmbh Retard formulation for pralnacasan
WO2007056442A1 (en) * 2005-11-07 2007-05-18 King Pharmaceuticals Research & Development, Inc. Compositions of stabilized ramipril in combination with another active agent
US20070124219A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized nutraceutical selection and packaging
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070128298A1 (en) * 2005-11-22 2007-06-07 Cowley Michael A Compositions and methods for increasing insulin sensitivity
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20070134321A1 (en) * 2004-05-21 2007-06-14 Lawrence Solomon Pharmaceutical tablets with height greater than width
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20070141155A1 (en) * 2004-05-21 2007-06-21 Lawrence Solomon Pharmaceutical tablets having height greater than width
US20070148237A1 (en) * 2005-11-28 2007-06-28 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
US20070174128A1 (en) * 2005-11-30 2007-07-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20070190147A1 (en) * 2004-05-21 2007-08-16 Lawrence Solomon Pharmaceutical tablets with active and inactive segments
US20070214008A1 (en) * 2005-11-30 2007-09-13 Searete Llc, A Limited Liability Corporation Of The State Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070264331A1 (en) * 2005-09-08 2007-11-15 Laboratorios Silanes, S.A De C.V. Stable pharmaceutical composition of immediate-release glimepiride and extended-release metformin
US20070281021A1 (en) * 2006-06-05 2007-12-06 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070289258A1 (en) * 2006-06-14 2007-12-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Individualized pharmaceutical selection and packaging
US20080003307A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US20080004905A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US20080033763A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to receiving nutraceutical associated information
US20080033762A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to transmission of nutraceutical associated information
US20080052114A1 (en) * 2005-11-30 2008-02-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US20080103746A1 (en) * 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US20080114577A1 (en) * 2005-11-30 2008-05-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems associated with nutraceutical related assays
US20080160001A1 (en) * 2005-03-28 2008-07-03 Pficker Pharmaceuticals Ltd. Antihypercholesterolemic Formulation with Less Side-Effects
US20080213368A1 (en) * 2004-12-27 2008-09-04 Eisai R & D Management Co., Ltd. Method for Stabilizing Anti-Dementia Drug
US20090202636A1 (en) * 2006-06-16 2009-08-13 Lek Pharmaceuticals D.D. Pharmaceutical Composition
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20090311325A1 (en) * 2006-04-10 2009-12-17 K.U.Leuven Research And Development Enhancing solubility and dissolution rate of poorly soluble drugs
US20100015222A1 (en) * 2008-03-11 2010-01-21 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2010081824A2 (en) 2009-01-14 2010-07-22 Lek Pharmaceuticals D.D. Active coating of pharmaceutical dosage forms
US20100196474A1 (en) * 2008-03-11 2010-08-05 Depomed, Inc. Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
US20110002985A1 (en) * 2007-08-13 2011-01-06 Abuse Deterrent Pharmaceutical, Llc Abuse resistant drugs, method of use and method of making
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US20110059170A1 (en) * 2006-11-09 2011-03-10 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US20110144145A1 (en) * 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
WO2013050339A1 (en) * 2011-10-03 2013-04-11 Ems S/A Pharmaceutical compositions of antihypertensives
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
WO2014017833A1 (en) * 2012-07-24 2014-01-30 Hanmi Pharm. Co., Ltd. Composite formulation for oral administration comprising metformin and rosuvastatin
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20140350488A1 (en) * 2012-01-23 2014-11-27 Bayer Oy Drug delivery system
US20140371282A1 (en) * 2004-02-11 2014-12-18 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailabililty
US20150190399A1 (en) * 2012-07-23 2015-07-09 Landsteiner Scientific S.A. De C.V. New differential-release pharmaceutical composition containing three active principles
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US9633575B2 (en) 2012-06-06 2017-04-25 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US20170161926A1 (en) * 2015-12-04 2017-06-08 Sap Se Rendering data visualizations in different analytical applications
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
WO2018064578A1 (en) * 2016-09-30 2018-04-05 Lynthera Corporation High-precision drug delivery by dual-domain ocular device
US10192176B2 (en) 2011-10-11 2019-01-29 Microsoft Technology Licensing, Llc Motivation of task completion and personalization of tasks and lists
US10238647B2 (en) 2003-04-29 2019-03-26 Nalpropion Pharmaceuticals, Inc. Compositions for affecting weight loss
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US10413514B2 (en) * 2014-04-08 2019-09-17 Overseas Pharmaceuticals, Ltd. Controlled-release solid preparation with partial coating
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US10857098B2 (en) 2017-06-16 2020-12-08 Kashiv Specialty Pharmaceuticals, Llc Gastroretentive dosage forms for sustained drug delivery
WO2021042865A1 (en) * 2019-09-06 2021-03-11 Triastek, Inc. Oral drug dosage forms having a desired pk profile and methods of designing and producing thereof
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US11129612B2 (en) * 2015-08-31 2021-09-28 Cilag Gmbh International Inducing tissue adhesions using surgical adjuncts and medicants
US11229606B2 (en) 2018-06-18 2022-01-25 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
US11826535B2 (en) 2015-08-31 2023-11-28 Cilag Gmbh International Medicant eluting adjuncts and methods of using medicant eluting adjuncts

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
JP2009516636A (en) * 2005-06-13 2009-04-23 エラン コーポレーション ピーエルシー Modified release ticlopidine composition
US8394845B2 (en) 2006-10-30 2013-03-12 Hanall Biopharma Co., Ltd. Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
EP2079452A4 (en) * 2006-10-30 2010-01-06 Hanall Pharmaceutical Co Ltd Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
AU2007314795B2 (en) * 2006-10-30 2012-02-16 Hanall Biopharma Co., Ltd. Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
JP2010534721A (en) * 2007-07-27 2010-11-11 ディポメド，インコーポレイティド Pulse type gastric retentive preparation
KR20090114322A (en) * 2008-04-29 2009-11-03 한올제약주식회사 Pharmaceutical formulation for treating cardiovascular disease
WO2009134056A2 (en) * 2008-04-29 2009-11-05 한올제약주식회사 Pharmaceutical formulation
JP5664993B2 (en) * 2009-08-28 2015-02-04 トーアエイヨー株式会社 Solid formulation containing glimepiride
KR101010325B1 (en) * 2009-12-17 2011-01-25 현대약품 주식회사 Pharmaceutical composition comprising telmisartan and hydrochlorothiazide
KR101597004B1 (en) * 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 Pharmaceutical combination comprising sustained-release type metformin and immediate-release type HMG-CoA reductase inhibitor
KR102229798B1 (en) * 2013-12-12 2021-03-19 한미약품 주식회사 Bilayered tablet composite formulation comprising metformin and losartan
RU2016151697A (en) 2014-06-02 2018-07-10 Тева Фармасьютикал Индастриз Лтд. GASTRADICINAL, REMAINABLE, GASTRIC-ARCHIVED MEDICINAL FORM
EP3277278B1 (en) 2015-04-02 2020-01-08 Theravance Biopharma R&D IP, LLC Combination dosage form of a mu opioid receptor antagonist and an opioid agent
CA3059210C (en) 2016-05-19 2022-07-19 The Regents Of The University Of California Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
IL266377B2 (en) 2016-12-02 2023-10-01 Clexio Biosciences Ltd Gastric residence system
KR102409102B1 (en) * 2017-07-17 2022-06-16 일라이 릴리 앤드 캄파니 pharmaceutical composition
EP3720537A1 (en) 2017-12-04 2020-10-14 Clexio Biosciences Ltd. Long acting gastric residence system
US20190350883A1 (en) * 2018-05-20 2019-11-21 Luan Chau Pharmaceutical Composition of Acetaminophen/Ibuprofen
KR102183669B1 (en) * 2019-03-26 2020-11-26 가톨릭대학교 산학협력단 Drug delivery carrier for dual drug release

Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024175A (en) * 1974-12-21 1977-05-17 Warner-Lambert Company Cyclic amino acids
US4292299A (en) * 1978-11-06 1981-09-29 Teijin Limited Slow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4786505A (en) * 1986-04-30 1988-11-22 Aktiebolaget Hassle Pharmaceutical preparation for oral use
US4891230A (en) * 1983-12-22 1990-01-02 Elan Corporation Plc Diltiazem formulation
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5549913A (en) * 1992-11-17 1996-08-27 Inverni Della Beffa S.P.A. Multilayer matrix systems for the controlled release of active principles
US5681583A (en) * 1993-07-09 1997-10-28 Apr Applied Pharma Research Sa Multilayered controlled-release oral solid pharmaceutical forms
US5780057A (en) * 1996-02-19 1998-07-14 Jagotec Ag Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US5861173A (en) * 1995-11-28 1999-01-19 Bayer Aktiengesellschaft Long-lasting release nifedipine preparation
US5922769A (en) * 1995-11-14 1999-07-13 Abiogen Pharma S.R.L. Glibenclamide-metformin combination for the treatment of diabetes mellitus of type II
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6031004A (en) * 1997-12-08 2000-02-29 Bristol-Myers Squibb Company Salts of metformin and method
US6054482A (en) * 1989-08-25 2000-04-25 Godecke Aktiengesellschaft Lactam-free amino acids
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6126969A (en) * 1996-02-27 2000-10-03 L. Perrigo Company Immediate release/sustained release compressed tablets
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US6159499A (en) * 1995-09-21 2000-12-12 Pharma Pass Llc Composition containing an acid-labile benzimidazole and process for its preparation
US6171618B1 (en) * 1996-05-29 2001-01-09 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US6183778B1 (en) * 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
US6183777B1 (en) * 1997-10-23 2001-02-06 Development Center For Biotechnology Controlled release tacrine dosage form
US6194000B1 (en) * 1995-10-19 2001-02-27 F.H. Faulding & Co., Limited Analgesic immediate and controlled release pharmaceutical composition
US6211205B1 (en) * 1995-06-20 2001-04-03 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same
US6274608B1 (en) * 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
US20010018070A1 (en) * 1997-06-06 2001-08-30 John W. Shell Extending the duration of drug release within the stomach during the fed mode
US6294690B1 (en) * 1997-10-07 2001-09-25 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
US20010036478A1 (en) * 2000-05-01 2001-11-01 Adjei Akwete L. Core formulation
US6372255B1 (en) * 1997-12-23 2002-04-16 Merck Patent Gesellschaft Tablet for instant and prolonged release of one or more active substances
US6780436B1 (en) * 1999-09-13 2004-08-24 Laboratorios Del Dr. Esteve, Sa Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound
US6814979B2 (en) * 1996-10-25 2004-11-09 Shire Laboratories, Inc. Osmotic drug delivery system

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA722664B (en) 1971-05-18 1973-01-31 Smith Kline French Lab Lyered bolus for animal husbandry providing for immediate and sustained release of medicament
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5213807A (en) 1990-05-03 1993-05-25 Chemburkar Pramod B Pharmaceutical composition containing ibuprofen and a prostaglandin
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
IT1255522B (en) 1992-09-24 1995-11-09 Ubaldo Conte COMPRESSED FOR THERAPEUTIC USE SUITABLE FOR SELLING ONE OR MORE ACTIVE SUBSTANCES WITH DIFFERENT SPEEDS
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
GB9402203D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US6074674A (en) * 1997-10-31 2000-06-13 University Of Kentucky Research Foundation Formulations for sustained-release of topical anesthetics and methods of making and using same
BR9908911A (en) * 1998-03-19 2001-10-02 Bristol Myers Squibb Co Biphasic system and distribution process by controlled release of high solubility pharmaceutical substances
FR2784583B1 (en) 1998-10-16 2002-01-25 Synthelabo PHARMACEUTICAL COMPOSITION WITH GASTRIC RESIDENCE AND CONTROLLED RELEASE
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
DE19927688A1 (en) 1999-06-17 2000-12-21 Gruenenthal Gmbh Multi-layered tablet containing tramadole and diclofenac, useful for treating pain, has separating layer between active ingredient layers
BE1012790A3 (en) 1999-07-19 2001-03-06 Solvay Hollow body and method of manufacturing hollow.
AU2277101A (en) 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
EP1330236A2 (en) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Formulation containing amoxicillin
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
PL370818A1 (en) * 2001-09-28 2005-05-30 Sun Pharmaceutical Industries Limited Dosage form for treatment of diabetes mellitus
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs

Patent Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024175A (en) * 1974-12-21 1977-05-17 Warner-Lambert Company Cyclic amino acids
US4292299A (en) * 1978-11-06 1981-09-29 Teijin Limited Slow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4891230A (en) * 1983-12-22 1990-01-02 Elan Corporation Plc Diltiazem formulation
US4786505A (en) * 1986-04-30 1988-11-22 Aktiebolaget Hassle Pharmaceutical preparation for oral use
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US4894476A (en) * 1988-05-02 1990-01-16 Warner-Lambert Company Gabapentin monohydrate and a process for producing the same
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US6054482A (en) * 1989-08-25 2000-04-25 Godecke Aktiengesellschaft Lactam-free amino acids
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5549913A (en) * 1992-11-17 1996-08-27 Inverni Della Beffa S.P.A. Multilayer matrix systems for the controlled release of active principles
US5681583A (en) * 1993-07-09 1997-10-28 Apr Applied Pharma Research Sa Multilayered controlled-release oral solid pharmaceutical forms
US6183778B1 (en) * 1993-09-21 2001-02-06 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
US6211205B1 (en) * 1995-06-20 2001-04-03 Takeda Chemical Industries, Ltd. Pharmaceutical composition
US6159499A (en) * 1995-09-21 2000-12-12 Pharma Pass Llc Composition containing an acid-labile benzimidazole and process for its preparation
US6248355B1 (en) * 1995-09-21 2001-06-19 Schwarz Pharma Ag Pharmaceutical composition containing an acid-labile omeprazole and process for its preparation
US6194000B1 (en) * 1995-10-19 2001-02-27 F.H. Faulding & Co., Limited Analgesic immediate and controlled release pharmaceutical composition
US5922769A (en) * 1995-11-14 1999-07-13 Abiogen Pharma S.R.L. Glibenclamide-metformin combination for the treatment of diabetes mellitus of type II
US5861173A (en) * 1995-11-28 1999-01-19 Bayer Aktiengesellschaft Long-lasting release nifedipine preparation
US5780057A (en) * 1996-02-19 1998-07-14 Jagotec Ag Pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids
US6126969A (en) * 1996-02-27 2000-10-03 L. Perrigo Company Immediate release/sustained release compressed tablets
US6171618B1 (en) * 1996-05-29 2001-01-09 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6814979B2 (en) * 1996-10-25 2004-11-09 Shire Laboratories, Inc. Osmotic drug delivery system
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
US20010018070A1 (en) * 1997-06-06 2001-08-30 John W. Shell Extending the duration of drug release within the stomach during the fed mode
US6294690B1 (en) * 1997-10-07 2001-09-25 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6183777B1 (en) * 1997-10-23 2001-02-06 Development Center For Biotechnology Controlled release tacrine dosage form
US6031004A (en) * 1997-12-08 2000-02-29 Bristol-Myers Squibb Company Salts of metformin and method
US6372255B1 (en) * 1997-12-23 2002-04-16 Merck Patent Gesellschaft Tablet for instant and prolonged release of one or more active substances
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6274608B1 (en) * 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
US6780436B1 (en) * 1999-09-13 2004-08-24 Laboratorios Del Dr. Esteve, Sa Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound
US20010036478A1 (en) * 2000-05-01 2001-11-01 Adjei Akwete L. Core formulation
US6270797B1 (en) * 2000-05-18 2001-08-07 Usv Limited Sustained release pharmaceutical composition containing glipizide and method for producing same

Cited By (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10238647B2 (en) 2003-04-29 2019-03-26 Nalpropion Pharmaceuticals, Inc. Compositions for affecting weight loss
WO2005058286A1 (en) * 2003-12-12 2005-06-30 Penwest Pharmaceuticals Co. Sustained release torsemide dosage forms
US20140371282A1 (en) * 2004-02-11 2014-12-18 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailabililty
US20070141155A1 (en) * 2004-05-21 2007-06-21 Lawrence Solomon Pharmaceutical tablets having height greater than width
US20080003285A1 (en) * 2004-05-21 2008-01-03 Lawrence Solomon Immediate Release Pharmaceutical Tablets With Height Greater Than Width
US7329418B2 (en) * 2004-05-21 2008-02-12 Accu Break Technologies, Inc. Pharmaceutical tablets having height greater than width
US20070190147A1 (en) * 2004-05-21 2007-08-16 Lawrence Solomon Pharmaceutical tablets with active and inactive segments
US8034380B2 (en) 2004-05-21 2011-10-11 Accu•Break Technologies, Inc. Immediate release pharmaceutical tablets with height greater than width
US7988996B2 (en) 2004-05-21 2011-08-02 Accu-Break Technologies, Inc. Pharmaceutical tablets with height greater than width
US20070134321A1 (en) * 2004-05-21 2007-06-14 Lawrence Solomon Pharmaceutical tablets with height greater than width
US7318935B2 (en) * 2004-05-21 2008-01-15 Accu-Break Technologies, Inc. Pharmaceutical tablets with active and inactive segments
US20100152164A1 (en) * 2004-12-27 2010-06-17 Eisai R&D Management Co., Ltd. Method For Stabilizing Anti-Dementia Drug
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US8481565B2 (en) 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20080213368A1 (en) * 2004-12-27 2008-09-04 Eisai R & D Management Co., Ltd. Method for Stabilizing Anti-Dementia Drug
US8507527B2 (en) 2004-12-27 2013-08-13 Eisai R & D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20080160001A1 (en) * 2005-03-28 2008-07-03 Pficker Pharmaceuticals Ltd. Antihypercholesterolemic Formulation with Less Side-Effects
US20070264331A1 (en) * 2005-09-08 2007-11-15 Laboratorios Silanes, S.A De C.V. Stable pharmaceutical composition of immediate-release glimepiride and extended-release metformin
US20080279934A1 (en) * 2005-10-08 2008-11-13 Sanofi-Aventis Deutschland Gmbh Extended release formulation for pralnacasan
US8231904B2 (en) 2005-10-08 2012-07-31 Sanofi-Aventis Deutschland Gmbh Extended release formulation for pralnacasan
KR101362679B1 (en) 2005-10-08 2014-02-13 사노피-아벤티스 도이칠란트 게엠베하 Retard formulation for pralnacasan
NO339360B1 (en) * 2005-10-08 2016-12-05 Sanofi Aventis Deutschland Extended release formulation comprising pralnacasan
WO2007042160A1 (en) * 2005-10-08 2007-04-19 Sanofi-Aventis Deutschland Gmbh Retard formulation for pralnacasan
US20070116762A1 (en) * 2005-11-07 2007-05-24 Wilson Edward S Compositions of stabilized ramipril in combination with another active agent
WO2007056442A1 (en) * 2005-11-07 2007-05-18 King Pharmaceuticals Research & Development, Inc. Compositions of stabilized ramipril in combination with another active agent
US20070128298A1 (en) * 2005-11-22 2007-06-07 Cowley Michael A Compositions and methods for increasing insulin sensitivity
US8815889B2 (en) 2005-11-22 2014-08-26 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US20070148237A1 (en) * 2005-11-28 2007-06-28 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
US20070214008A1 (en) * 2005-11-30 2007-09-13 Searete Llc, A Limited Liability Corporation Of The State Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20080210748A1 (en) * 2005-11-30 2008-09-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware, Systems and methods for receiving pathogen related information and responding
US20070124219A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized nutraceutical selection and packaging
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080033763A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to receiving nutraceutical associated information
US8068991B2 (en) 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US20080114577A1 (en) * 2005-11-30 2008-05-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems associated with nutraceutical related assays
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20070174128A1 (en) * 2005-11-30 2007-07-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080033762A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to transmission of nutraceutical associated information
US20080103746A1 (en) * 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US20080052114A1 (en) * 2005-11-30 2008-02-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US20110059175A9 (en) * 2006-04-10 2011-03-10 K.U.Leuven Research And Development Enhancing solubility and dissolution rate of poorly soluble drugs
US20090311325A1 (en) * 2006-04-10 2009-12-17 K.U.Leuven Research And Development Enhancing solubility and dissolution rate of poorly soluble drugs
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9107837B2 (en) 2006-06-05 2015-08-18 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070281021A1 (en) * 2006-06-05 2007-12-06 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20070289258A1 (en) * 2006-06-14 2007-12-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Individualized pharmaceutical selection and packaging
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US8685452B2 (en) 2006-06-16 2014-04-01 Lek Pharmaceuticals D.D. Pharmaceutical composition
EP2269583A1 (en) * 2006-06-16 2011-01-05 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
US9622976B2 (en) 2006-06-16 2017-04-18 Lek Pharmaceuticals D.D. Pharmaceutical composition
US20090202636A1 (en) * 2006-06-16 2009-08-13 Lek Pharmaceuticals D.D. Pharmaceutical Composition
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20080003307A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US20080004905A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US8318788B2 (en) 2006-11-09 2012-11-27 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US20110059170A1 (en) * 2006-11-09 2011-03-10 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US8722085B2 (en) 2006-11-09 2014-05-13 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US8088786B2 (en) 2006-11-09 2012-01-03 Orexigen Therapeutics, Inc. Layered pharmaceutical formulations
US20110002985A1 (en) * 2007-08-13 2011-01-06 Abuse Deterrent Pharmaceutical, Llc Abuse resistant drugs, method of use and method of making
US10736850B2 (en) * 2007-08-13 2020-08-11 Ohemo Life Sciences Inc. Abuse resistant oral opioid formulations
US20100015222A1 (en) * 2008-03-11 2010-01-21 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8668929B2 (en) 2008-03-11 2014-03-11 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8394408B2 (en) 2008-03-11 2013-03-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20100196474A1 (en) * 2008-03-11 2010-08-05 Depomed, Inc. Gastric Retentive Extended-Release Dosage Forms Comprising Combinations of a Non-Opioid Analgesic and an Opioid Analgesic
US8377453B2 (en) 2008-03-11 2013-02-19 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20110144145A1 (en) * 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US11324741B2 (en) 2008-05-30 2022-05-10 Nalpropion Pharmaceuticals Llc Methods for treating visceral fat conditions
EP2210595A1 (en) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
WO2010081824A2 (en) 2009-01-14 2010-07-22 Lek Pharmaceuticals D.D. Active coating of pharmaceutical dosage forms
WO2010081824A3 (en) * 2009-01-14 2011-01-13 Lek Pharmaceuticals D.D. Active coating of pharmaceutical dosage forms
CN102348455A (en) * 2009-01-14 2012-02-08 力奇制药公司 Active coating of pharmaceutical dosage forms
US20110052685A1 (en) * 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US11033543B2 (en) 2010-01-11 2021-06-15 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
US10322121B2 (en) 2010-01-11 2019-06-18 Nalpropion Pharmaceuticals, Inc. Methods of providing weight loss therapy in patients with major depression
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9468636B2 (en) 2011-05-17 2016-10-18 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US9539328B2 (en) 2011-05-17 2017-01-10 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9433582B2 (en) 2011-05-17 2016-09-06 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US9629837B2 (en) 2011-05-17 2017-04-25 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
GB2509470A (en) * 2011-10-03 2014-07-02 Ems Sa Pharmaceutical compositions of antihypertensives
WO2013050339A1 (en) * 2011-10-03 2013-04-11 Ems S/A Pharmaceutical compositions of antihypertensives
US10192176B2 (en) 2011-10-11 2019-01-29 Microsoft Technology Licensing, Llc Motivation of task completion and personalization of tasks and lists
US20140350488A1 (en) * 2012-01-23 2014-11-27 Bayer Oy Drug delivery system
US10500381B2 (en) * 2012-01-23 2019-12-10 Bayer Oy Drug delivery system
US9633575B2 (en) 2012-06-06 2017-04-25 Orexigen Therapeutics, Inc. Methods of treating overweight and obesity
US10403170B2 (en) 2012-06-06 2019-09-03 Nalpropion Pharmaceuticals, Inc. Methods of treating overweight and obesity
US20150190399A1 (en) * 2012-07-23 2015-07-09 Landsteiner Scientific S.A. De C.V. New differential-release pharmaceutical composition containing three active principles
WO2014017833A1 (en) * 2012-07-24 2014-01-30 Hanmi Pharm. Co., Ltd. Composite formulation for oral administration comprising metformin and rosuvastatin
US10413514B2 (en) * 2014-04-08 2019-09-17 Overseas Pharmaceuticals, Ltd. Controlled-release solid preparation with partial coating
US11839733B2 (en) 2015-08-31 2023-12-12 Cilag Gmbh International Medicant eluting adjuncts and methods of using medicant eluting adjuncts
US11826535B2 (en) 2015-08-31 2023-11-28 Cilag Gmbh International Medicant eluting adjuncts and methods of using medicant eluting adjuncts
US11129612B2 (en) * 2015-08-31 2021-09-28 Cilag Gmbh International Inducing tissue adhesions using surgical adjuncts and medicants
US20170161926A1 (en) * 2015-12-04 2017-06-08 Sap Se Rendering data visualizations in different analytical applications
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US10010529B2 (en) 2016-03-24 2018-07-03 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US20190224045A1 (en) * 2016-09-30 2019-07-25 Lynthera Corporation High-precision drug delivery by dual-domain ocular device
CN109843229A (en) * 2016-09-30 2019-06-04 领视药公司 By the pinpoint accuracy drug delivery of dual domain device for eyes
US10617559B2 (en) * 2016-09-30 2020-04-14 Lynthera Corporation High-precision drug delivery by dual-domain ocular device
WO2018064578A1 (en) * 2016-09-30 2018-04-05 Lynthera Corporation High-precision drug delivery by dual-domain ocular device
US11173064B2 (en) * 2016-09-30 2021-11-16 Lynthera Corporation High-precision drug delivery by dual-domain ocular device
US10918597B2 (en) 2017-06-16 2021-02-16 Kashiv Specialty Pharmaceuticals, Llc Gastroretentive dosage forms for sustained drug delivery
US11478425B2 (en) 2017-06-16 2022-10-25 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
US12042559B2 (en) * 2017-06-16 2024-07-23 Amneal Complex Products Research Llc Gastroretentive dosage forms for sustained drug delivery
US10588863B2 (en) 2017-06-16 2020-03-17 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10857098B2 (en) 2017-06-16 2020-12-08 Kashiv Specialty Pharmaceuticals, Llc Gastroretentive dosage forms for sustained drug delivery
US10744093B2 (en) 2017-06-16 2020-08-18 Kashiv Biosciences, Llc Extended release compositions comprising pyridostigmine
US10987311B2 (en) 2017-06-16 2021-04-27 Kashiv Specialty Pharmaceuticals, Llc Extended release compositions comprising pyridostigmine
US11229606B2 (en) 2018-06-18 2022-01-25 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
US11666536B2 (en) 2018-08-30 2023-06-06 Amneal Complex Products Research Llc Extended release compositions comprising pyridostigmine
US11389398B2 (en) 2019-05-14 2022-07-19 Clexio Biosciences Ltd. Gastroretentive treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2020230089A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
WO2021042865A1 (en) * 2019-09-06 2021-03-11 Triastek, Inc. Oral drug dosage forms having a desired pk profile and methods of designing and producing thereof
CN112638367A (en) * 2019-09-06 2021-04-09 南京三迭纪医药科技有限公司 Oral pharmaceutical dosage form capable of achieving target PK profile, design and preparation method thereof
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Also Published As

Publication number Publication date
EP1646368A1 (en) 2006-04-19
AU2004258903A1 (en) 2005-02-03
NZ544615A (en) 2009-02-28
JP2007524644A (en) 2007-08-30
US20170202817A1 (en) 2017-07-20
US20120263792A1 (en) 2012-10-18
US20160030352A1 (en) 2016-02-04
US8685450B2 (en) 2014-04-01
KR20060064048A (en) 2006-06-12
EP1646368A4 (en) 2010-07-07
TW200510001A (en) 2005-03-16
US9572780B2 (en) 2017-02-21
MXPA06000526A (en) 2006-03-30
CA2531721A1 (en) 2005-02-03
US20140186515A1 (en) 2014-07-03
WO2005009413A1 (en) 2005-02-03
CA2531721C (en) 2013-06-11
US8999388B2 (en) 2015-04-07

Similar Documents

Publication Publication Date Title
US9572780B2 (en) Dual drug dosage forms with improved separation of drugs
US6682759B2 (en) Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US8911781B2 (en) Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
WO2011111818A1 (en) Sustained release type pharmaceutical composition containing mosapride or salt thereof
US20060127478A1 (en) Oral dosage formulation
UA112632C2 (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
JP2003521507A (en) Shell-core dosage form approaching zero order drug release
EP1524963A2 (en) Novel floating dosage form
WO2004016250A1 (en) Sustained release pharmaceutical composition of a cephalosporin antibiotic
EP2010158B1 (en) Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
AU2011205024B2 (en) Multiple PPI dosage form
CA2463168A1 (en) An antispasmodic agent spaced drug delivery system

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEPOMED, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIM, JONG;SHELL, JOHN N.;LOUIE-HELM, JENNY;REEL/FRAME:014158/0960

Effective date: 20031013

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION

AS Assignment

Owner name: DEERFIELD PRIVATE DESIGN FUND III, L.P., NEW YORK

Free format text: SECURITY INTEREST;ASSIGNOR:DEPOMED, INC.;REEL/FRAME:035355/0039

Effective date: 20150402

AS Assignment

Owner name: ASSERTIO THERAPEUTICS, INC., ILLINOIS

Free format text: MERGER;ASSIGNOR:DEPOMED, INC.;REEL/FRAME:047322/0843

Effective date: 20180810

AS Assignment

Owner name: ASSERTIO THERAPEUTICS, INC., ILLINOIS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBERS 09402976, 10196590, 11562002,11562173,12047388,13078575,13541314,13541325, 14747289 PREVIOUSLY RECORDED ON REEL 047322 FRAME 0843. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER;ASSIGNOR:DEPOMED, INC.;REEL/FRAME:049110/0550

Effective date: 20180810

AS Assignment

Owner name: ASSERTIO THERAPEUTICS, INC. (F/K/A DEPOMED, INC.), ILLINOIS

Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:DEERFIELD PRIVATE DESIGN FUND III, L.P., AS COLLATERAL AGENT;REEL/FRAME:051930/0778

Effective date: 20200213